155 related articles for article (PubMed ID: 28049106)
1. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
de Jonge MM; Mooyaart AL; Vreeswijk MP; de Kroon CD; van Wezel T; van Asperen CJ; Smit VT; Dekkers OM; Bosse T
Eur J Cancer; 2017 Feb; 72():215-225. PubMed ID: 28049106
[TBL] [Abstract][Full Text] [Related]
2. BRCA germline mutations in women with uterine serous carcinoma--still a debate.
Lavie O; Ben-Arie A; Segev Y; Faro J; Barak F; Haya N; Auslender R; Gemer O
Int J Gynecol Cancer; 2010 Dec; 20(9):1531-4. PubMed ID: 21119368
[TBL] [Abstract][Full Text] [Related]
3. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
4. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma.
Bruchim I; Amichay K; Kidron D; Attias Z; Biron-Shental T; Drucker L; Friedman E; Werner H; Fishman A
Int J Gynecol Cancer; 2010 Oct; 20(7):1148-53. PubMed ID: 21206239
[TBL] [Abstract][Full Text] [Related]
6. Germline mutations of the DNA repair pathways in uterine serous carcinoma.
Frimer M; Levano KS; Rodriguez-Gabin A; Wang Y; Goldberg GL; Horwitz SB; Hou JY
Gynecol Oncol; 2016 Apr; 141(1):101-7. PubMed ID: 27016235
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 germline mutations in women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben Arie A; Renbaum P; Levy-Lahad E; Beller U
Obstet Gynecol; 2000 Jul; 96(1):28-32. PubMed ID: 10862837
[TBL] [Abstract][Full Text] [Related]
8. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
Pennington KP; Walsh T; Lee M; Pennil C; Novetsky AP; Agnew KJ; Thornton A; Garcia R; Mutch D; King MC; Goodfellow P; Swisher EM
Cancer; 2013 Jan; 119(2):332-8. PubMed ID: 22811390
[TBL] [Abstract][Full Text] [Related]
9. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
10. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
[TBL] [Abstract][Full Text] [Related]
11. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Hornreich G; Beller U; Lavie O; Renbaum P; Cohen Y; Levy-Lahad E
Gynecol Oncol; 1999 Nov; 75(2):300-4. PubMed ID: 10525392
[TBL] [Abstract][Full Text] [Related]
12. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Lavie O; Ben-Arie A; Pilip A; Rennert G; Cohen Y; Feiner B; Auslnader R
Gynecol Oncol; 2005 Nov; 99(2):486-8. PubMed ID: 16051327
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ; Bewtra C
Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
[TBL] [Abstract][Full Text] [Related]
14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical loss of BRCA1 protein in uterine serous carcinoma.
Hecht JL; Konstantinopoulos PA; Awtrey CS; Soslow RA
Int J Gynecol Pathol; 2014 May; 33(3):282-7. PubMed ID: 24681740
[TBL] [Abstract][Full Text] [Related]
16. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
Goshen R; Chu W; Elit L; Pal T; Hakimi J; Ackerman I; Fyles A; Mitchell M; Narod SA
Gynecol Oncol; 2000 Dec; 79(3):477-81. PubMed ID: 11104623
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
18. No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report.
Pejovic T; Koul A; Olsen D; Chambers JT
Eur J Gynaecol Oncol; 2001; 22(5):336-8. PubMed ID: 11766733
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
20. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]